By Bhanvi Satija Oct 2 (Reuters) – Chinese biotech company Abogen said on Friday it has signed a licensing deal worth up to $7.8 billion with Novartis to develop messenger RNA-based therapies,
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Oct 2 (Reuters) - Punjab National Bank: * PUNJAB NATIONAL BANK - DOMESTIC ADVANCES AS…
VIDEO SHOWS: HIGHLIGHTS FROM SECOND ROUND ACTION FROM CHINA OPEN - A WTA 1000 TOURNAMENT…
By Leila Miller BUENOS AIRES, Oct 2 (Reuters) - Buenos Aires is hosting its first…
By Ange Aboa ABIDJAN, Oct 2 (Reuters) - Top cocoa grower Ivory Coast's main crop…
By Foo Yun Chee BRUSSELS, Oct 2 (Reuters) - Chinese e-commerce giant JD.com is set…
By Darshan Kumar R and Ragini Mathur Oct 2 (Reuters) - Canada's main stock index…